Background: Neonatal sepsis is one of the major causes of morbidity and mortality in the newborn. Early diagnosis and treatment are crucial in the management of neonatal sepsis. Blood culture, the gold standard, takes long time and lack sensitivity. Hematological sepsis score is a simple score obtained by combining routinely available tests and is rapid, non-expensive and has shown good correlation with blood culture. With this background the study was carried out to evaluate hematological changes in neonatal sepsis and to analyse the diagnostic utility of hematological scoring system (HSS) and its correlation with C-reactive protein and blood culture in neonatal sepsis. Methods:The study included 200 neonates admitted to Neonatal Intensive Care Unit with clinical suspicion of neonatal sepsis. CBC, Peripheral blood smear, CRP and Blood culture were obtained from all the neonate. Hematological sepsis score was calculated, and its sensitivity and specificity were obtain using blood culture as gold standard.Result: We screened 200 neonates with suspected neonatal sepsis. Blood culture was positive in 101 (50.5%) and HSS score >2 was found in 80 (40%) neonates. CRP and HSS had sensitivity of 84.15% and 72.27% and specificity of 68.68% and 92.92% respectively. Conclusion:Our study shows that HSS had fairly good sensitivity and specificity for neonatal sepsis screening and HHS can be utilized for neonatal sepsis screening.

priately identify the best treatment has become more important. The purpose of this analysis is to compare the rates of testing among HN patients on two key biomarker tests PD-L1 and HPV status in the US and 5 European (EU5) countries. MethodS: A retrospective medical chart review of patients with HN in the US (n= 606) and EU5 (France, Germany, Italy, Spain, UK; n= 1,000) was conducted between 7/2016 and 6/2017. Physicians randomly selected patient charts currently on an anti-cancer regimen and extracted data on patient demographics, disease status, treatment patterns, and biomarker status. ReSultS: Of the 1,606 HN patients included in this analysis, the US and EU5 had different gender distributions (percent male US: 68%, EU: 81%, p= < 0.01), but similar average ages (mean (SD) US: 62.86 (8.25), EU: 63.32 (8.81) between groups (p= 0.29). When identifying PD-L1 status between the countries, significantly more patients in the EU5 had never been tested (76%, US: 61%, p= < 0.01). Of those who were tested in the US (n= 238) and EU5 (n= 244), 63% of patients in the US were positive compared to only 35% in the EU5 (p= < 0.01). HPV results showed no differences in the testing rate (US: 89%, EU5: 91%, p= 0.54), but of those tested (US: 535, EU5: 908) significantly more HN patients tested HPV positive in the US (26%) than in the EU5 (16%, p= < 0.01). ConCluSionS: As new advanced therapies become available the importance of biomarker testing among HN cancer patients will continue to grow. Understanding the differences in how tests are used as well as patient test results by region is vital in the development and testing process.